Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab) Oct 10, 2023 01:30AM
Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors May 25, 2023 01:30AM
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 Nov 14, 2022 02:00AM
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA® Jun 28, 2022 02:00AM
Transgene and BioInvent Announce Positive Progress for BT-001 Jun 27, 2022 02:00AM


Jun 16, 2022 12:00AM Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
Mar 9, 2022 02:00AM Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
Jan 20, 2022 02:00AM Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade
Nov 9, 2021 08:00AM Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
Oct 1, 2021 09:00AM Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
May 27, 2021 02:41AM BioInvent and Transgene receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
May 27, 2021 02:30AM Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors
Mar 1, 2021 01:52AM BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
Mar 1, 2021 01:30AM Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors
Dec 21, 2020 02:55AM BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors
Nov 9, 2020 12:00PM Transgene And BioInvent Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
Nov 9, 2020 08:15AM BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
Oct 15, 2020 03:06AM BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
Oct 15, 2020 02:30AM Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
May 15, 2020 02:47AM BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors
Mar 3, 2020 03:02AM BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Dec 11, 2019 02:57AM BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors
Dec 11, 2019 02:15AM Transgene and BioInvent Announce Compelling Preclinical Data For BT-001 in Solid Tumors
Oct 23, 2019 07:45AM BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million)
Mar 26, 2019 03:59AM BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
Mar 26, 2019 03:30AM Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
Nov 13, 2018 11:50AM BioInvent Announces Publication of Data in Leading Cancer Journal Immunity
Nov 7, 2018 12:10PM Transgene and BioInvent Present Positive Data at the SITC, Supporting the Co-development of a Next-generation Oncolytic Virus Encoding for an Anti-CTLA-4 Antibody